I changed my mind about Washout after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary way it happens.
Coming back to: Washout: how long is long enough, and for what purpose posts 31–60
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Collapsed as off-topic by two members at trust level 3 or above
The arithmetic in post #31 is right; the assumption feeding it is the part to check.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
I looked this up rather than remembered it, which is the right order.
Post #31 put the caveat in the right place and I want to underline it.
On Washout, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.
If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.
The most useful thing anyone has posted about Washout in this category was a table of what had been measured and by whom. That is what I would want again.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
It is the sort of thing that seems obvious in retrospect and was not at the time.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
The arithmetic in post #40 is right; the assumption feeding it is the part to check.
Practical answer on Washout, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Answering the question post #38 raises rather than the one it answers.
Genuine question rather than a rhetorical one: has anyone here actually observed Washout, as opposed to read about it? The thread is long and I cannot tell.
Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady state and how long it takes to clear after stopping.
Second this, and I would have said it less carefully.
A methods point on Washout rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
Everything in post #42 holds. The case it does not cover is the one I have.
Two people in this thread mean different things by Washout and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
I have changed my mind on this once already, so take it as current rather than settled.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
Fine by me. I had wanted a stronger conclusion and there is not one available.
Since Washout keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more direct experience will review it.
On post #50 — agreed on the reasoning, with one qualification.
What would change my mind on Washout is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.
Picking up post #50: that is the part I would want checked first.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
Nothing above should be read as advice about what anyone else should do.
Source for the Washout figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
This follows post #53 rather than contradicting it.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
The step people skip is the one I have spelled out.
Practical note on Washout: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance would allow.
I disagree with the framing of Washout above, and I think it is a substantive disagreement rather than a terminological one. Setting out why, so it can be checked.
The reasoning depends on an assumption that is doing a lot of work and is never stated. If the assumption holds, the conclusion follows. I do not think it holds generally.
Grateful for the specificity. Vague answers to this question are what sent me looking.
Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady state and how long it takes to clear after stopping.
I would put a moderate confidence on that and no more.